Nanoparticulate Formulation for Diagnosis and / or Treatment of Cancer
Non-Confidential description of the invention
The present invention presents a combination therapy based on Niclosamide and Doxorubicin for improved treatment of breast cancer. Niclosamide, an FDA approved anti-helminthic drug is repurposed as a Wnt signaling inhibitor for cancer therapy along with doxorubicin which is a first line treatment for breast cancer. We found that combination of Niclosamide and doxorubicin caused synergistically enhanced death of breast cancer cells irrespective of their clinical subtype (viz. HR positive, HER2 positive and triple negative). Since single agent therapy proves to be inefficient in treating cancer and combination therapy is the need of the hour in clinics, such a combination therapy holds great potential to be an effective treatment option for breast cancer.Breast cancer is the leading cause of cancer related deaths amongst women both globally as well as in India. Present treatment options for breast cancer proves to be inefficient as cancer cells develop resistance towards chemotherapeutic agents, cause tumor relapse and finally leads to very poor overall survival. This highlights the need to develop an efficient treatment option for breast cancer. The present invention presents a combination therapy based on Niclosamide and Doxorubicin. Niclosamide, an FDA approved anti-helminthic, is known to inhibit Wnt signaling in cancer cells and doxorubicin is a first line treatment for breast cancer. In the present invention, we have repurposed Niclosamide for cancer therapy. We found that combination of Niclosamide and Doxorubicin caused synergistically enhanced death of all breast cancer cells irrespective of their clinical subtypes. Mechanism of synergism was also unveiled which involves downregulation of Wnt signaling, generation of ROS species and cell cycle arrest at G0/G1 phase. Since Wnt signaling is upregulated in various other cancer types, the developed therapy holds potential to be used in the treatment of other cancer types as well.
Dr. Dhirendra S. Katti (BSBE), Ms. Garima Lohiya (PhD. Student, BSBE), Mr. Vishesh Sood (PhD. Student, BSBE)
Date of Filing
Patent application filed